Comprehensive Joint Modeling of First-Line Therapeutics in Non-Small Cell Lung Cancer
medRxiv (Cold Spring Harbor Laboratory)(2024)
摘要
First-line antiproliferatives for non-small cell lung cancer (NSCLC) have a
relatively high failure rate due to high intrinsic resistance rates and
acquired resistance rates to therapy. 57
disease due to the tendency of early-stage NSCLC to be asymptomatic. For
patients first diagnosed with metastatic disease the 5-year survival rate is
approximately 5
computer-based tools for optimizing individual therapy, we have collated data
from 11 different clinical trials in NSCLC and developed a semi-mechanistic,
clinical model of NSCLC growth and pharmacodynamics relative to the various
therapeutics represented in the study. In this study, we have produced
extremely precise estimates of clinical parameters fundamental to cancer
modeling such as the rate of acquired resistance to various pharmaceuticals,
the relationship between drug concentration and rate of cancer cell death, as
well as the fine temporal dynamics of anti-VEGF therapy. In the simulation sets
documented in this study, we have used the model to make meaningful
descriptions of efficacy gain in making bevacizumab-antiproliferative
combination therapy sequential, over a series of days, rather than concurrent.
更多查看译文
关键词
lung cancer,comprehensive joint modeling,first-line,non-small
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要